DPFS Devolved Portfolio (Pilot)
Lead Research Organisation:
University of Dundee
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
This is an award of a devolved portfolio under a pilot phase, as part of the implementation of the Development Pathway Funding Scheme (DPFS). DPFS Devolved Portfolios are block awards for specific universities to support goal-orientated translational research projects. The award allows universities to allocate the money to different translational projects more responsively based on their relative progress. For example the university might decide to stop a particular project and recycle the money allocated to it into other proposals. All projects supported by the Portfolio fall within the remit of the Development Pathway Funding Scheme (DPFS).
People |
ORCID iD |
Michael Ferguson (Principal Investigator) |
Publications
Navratilova I
(2011)
Screening for GPCR Ligands Using Surface Plasmon Resonance.
in ACS medicinal chemistry letters
Cox B
(2012)
MR real-time tracking of hepatic motion during respiration in a Thiel Soft-fix cadaver
in Biomedical Engineering / Biomedizinische Technik
Eisma R
(2013)
Liver displacement during ventilation in Thiel embalmed human cadavers - a possible model for research and training in minimally invasive therapies.
in Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
Aristotelous T
(2013)
Discovery of ß2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor.
in ACS medicinal chemistry letters
Tardif S
(2014)
Clinically relevant enhancement of human sperm motility using compounds with reported phosphodiesterase inhibitor activity.
in Human reproduction (Oxford, England)
Gueorguieva MJ
(2014)
MRI of Thiel-embalmed human cadavers.
in Journal of magnetic resonance imaging : JMRI
Cox B
(2014)
E-036 Cadaveric Flow Model for Endovascular Simulated Interventions
in Journal of NeuroInterventional Surgery
Pawellek A
(2014)
Identification of small molecule inhibitors of pre-mRNA splicing.
in The Journal of biological chemistry
Buciuc R
(2014)
P-018 MRI-based Endovascular Navigation in a Flow and Cadaveric Model; Feasibility Study
in Journal of NeuroInterventional Surgery
Beauchamp E
(2020)
Targeting N-myristoylation for therapy of B-cell lymphomas
in Nature Communications
Description | MRI guided DBS and Targeted Drug Delivery (www.IGI-TDD.eu) |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Influenced training of practitioners or researchers |
URL | http://www.IGI-TDD.eu |
Description | CASE studentship |
Amount | £92,173 (GBP) |
Funding ID | BB/JO11770/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2013 |
End | 05/2017 |
Description | CRUK programme grant |
Amount | £1,388,746 (GBP) |
Funding ID | C303/A14301 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2012 |
End | 09/2017 |
Description | Chemistry Catalyst Fund |
Amount | £18,897 (GBP) |
Organisation | Scottish Universities Life Sciences Alliance |
Sector | Academic/University |
Country | United Kingdom |
Start | 11/2011 |
End | 06/2012 |
Description | Chemistry Catalyst Fund |
Amount | £15,861 (GBP) |
Organisation | Scottish Universities Life Sciences Alliance |
Sector | Academic/University |
Country | United Kingdom |
Start | 01/2012 |
End | 12/2012 |
Description | Chemistry Catalyst Fund |
Amount | £13,557 (GBP) |
Organisation | Scottish Universities Life Sciences Alliance |
Sector | Academic/University |
Country | United Kingdom |
Start | 01/2012 |
End | 12/2012 |
Description | Chemistry Catalyst Fund |
Amount | £18,000 (GBP) |
Organisation | Scottish Universities Life Sciences Alliance |
Sector | Academic/University |
Country | United Kingdom |
Start | 01/2011 |
End | 12/2011 |
Description | Confidence in Concept 2012 |
Amount | £750,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2013 |
End | 06/2014 |
Description | Confidence in Concept 2013 |
Amount | £800,000 (GBP) |
Funding ID | MC_PC_13061 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2014 |
End | 08/2015 |
Description | Confidence in Concept 2014 |
Amount | £700,000 (GBP) |
Funding ID | MC_PC_14099 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2015 |
End | 08/2016 |
Description | Darwin Trust bequest |
Amount | £100,000 (GBP) |
Organisation | British Society for the History of Science (BSHS) |
Department | Darwin Trust of Edinburgh |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2015 |
End | 09/2016 |
Description | Developmental Pathway Funding Scheme |
Amount | £282,826 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2011 |
End | 09/2013 |
Description | Drug discovery |
Amount | £9,640 (GBP) |
Organisation | Tenovus Cancer Care |
Department | Tenovus Scotland |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2012 |
End | 10/2012 |
Description | EC FP7 Cooperation |
Amount | £614,248 (GBP) |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 03/2011 |
End | 02/2016 |
Description | EC FP7 Cooperation |
Amount | £873,623 (GBP) |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 01/2014 |
End | 12/2017 |
Description | Healthcare Technology Challenges for Engineering |
Amount | £454,600 (GBP) |
Funding ID | EP/K020013/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2013 |
End | 03/2016 |
Description | Healthcare Technology Challenges for Engineering |
Amount | £924,870 (GBP) |
Funding ID | EP/K020250/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 06/2013 |
End | 12/2014 |
Description | Innovative Medicines Initiative (IMI) |
Amount | € 1,000,000 (EUR) |
Organisation | European Commission |
Department | Seventh Framework Programme (FP7) |
Sector | Public |
Country | European Union (EU) |
Start | 01/2013 |
End | 12/2017 |
Description | Innovative therapeutics |
Amount | £200,000 (GBP) |
Organisation | Charles Wolfson Charitable Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2012 |
End | 04/2014 |
Description | Institutional Strategic Support Fund |
Amount | £275,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2011 |
End | 09/2012 |
Description | Institutional Strategic Support Fund Y2 |
Amount | £275,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2012 |
End | 09/2013 |
Description | Institutional Strategic Support Fund Y3 |
Amount | £275,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2013 |
End | 09/2014 |
Description | Institutional Strategic Support Fund Y4-5 |
Amount | £550,000 (GBP) |
Organisation | Wellcome Trust |
Department | Wellcome Trust Institutional Strategic Support Fund |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2014 |
End | 09/2016 |
Description | MRC Project Grant |
Amount | £418,900 (GBP) |
Funding ID | MR/K013343/1 |
Organisation | Medical Research Council (MRC) |
Department | The Mary Lyon Centre |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2013 |
End | 03/2016 |
Description | Medical device |
Amount | £130,000 (GBP) |
Organisation | Dr Hadwen Trust (DHT) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2011 |
End | 10/2014 |
Description | NRS NHS Research Fellowh |
Amount | £148,000 (GBP) |
Organisation | NHS Research Scotland |
Sector | Public |
Country | United Kingdom |
Start | 03/2013 |
End | 03/2016 |
Description | Project grant |
Amount | £99,000 (GBP) |
Organisation | Tenovus Cancer Care |
Department | Tenovus Scotland |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2014 |
End | 06/2016 |
Description | Strategic Award (DGEM) |
Amount | £1,670,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2012 |
End | 06/2017 |
Title | GPCR Ligand screen |
Description | Use of established methodology for new use. |
Type Of Material | Technology assay or reagent |
Provided To Others? | No |
Impact | Publication, new collaboration and funding leveraged. |
Title | MR-guided procedure |
Description | New tool for development of workflow of MR guided vascular interventons and validation of MRI guided Focused Ultrsound on moving organs in perfused Thiel embalmed cadavers. |
Type Of Material | Model of mechanisms or symptoms - human |
Year Produced | 2013 |
Provided To Others? | Yes |
Impact | Better model for vascular interventions and Focused Ultrasound of Moving Organs provides an alternative to animal models. |
Title | Madrasin |
Description | Madrasin is a highly characterised small molecule modulator of alternative splicing. |
Type Of Material | Technology assay or reagent |
Year Produced | 2015 |
Provided To Others? | Yes |
Impact | The splicing field has been hapmered by the lack of a robust chemical tool to study the biology. Madrasin appears to fit the requirements of the community with multipe groups able to recapitulate its effects. The paper describing the discovery and characterisation of Madrasin has been cited 9 times to date. |
URL | http://www.sigmaaldrich.com/catalog/product/sigma/sml1409?lang=en®ion=GB |
Title | Psoriasis cohort |
Description | Cohort of psoriasis patients for genetic research |
Type Of Material | Database/Collection of data |
Provided To Others? | No |
Impact | Cohort under development . It will used to perform pharmacogenomic profiling for treatment effects. |
Description | CRUK screen NRF2 |
Organisation | Cancer Research UK |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Expertise and specialist systems for the investigation of NRF2 biology |
Collaborator Contribution | Compound library screening and follow on drug discovery resource and expertise |
Impact | Too early |
Start Year | 2013 |
Description | Cancer follow on study |
Organisation | University of Alberta |
Country | Canada |
Sector | Academic/University |
PI Contribution | Supply of compounds and data. |
Collaborator Contribution | Broadening observations into other cancer types. |
Impact | Publications and two grant applications in progress. |
Start Year | 2012 |
Description | Discovery Partnership ( RT) |
Organisation | GlaxoSmithKline (GSK) |
Department | Discovery Partnerships with Academia |
Country | Global |
Sector | Private |
PI Contribution | University of Dundee licenced the IP around the chemistry and biology debveloped in under MRC-DPFS funding. The University of Dundee team (The Drug Discovery Unit and Prof Irwin McLean's group) are providing biology and chemistry expertise. |
Collaborator Contribution | GSK are leading the drug discovery project, providing funding (for both Dundee nad GSK activities), expertise and access to equipment and models. |
Impact | Project closed due to failure to meet key milestone. IP around lead compounds developed during the colaboration was assigned to Dundee along with associated data. Details are confidential. Project has become the subject of a second commercial partnership (with the company Pfizer in this case). Discussed as a separate output. |
Start Year | 2011 |
Description | Discovery Partnership (HD) |
Organisation | GlaxoSmithKline (GSK) |
Country | Global |
Sector | Private |
PI Contribution | Provide biology and assay expertise for drug discovery. |
Collaborator Contribution | Drug discovery -compound design and screening. |
Impact | Milestones were all achieved. Lead optimisation halted due to lack of conclusive cellular data. |
Start Year | 2011 |
Description | Drug Discovery partnership (Pfizer-RT project) |
Organisation | Pfizer Ltd |
Department | Orphan & Genetic Diseases Research Unit Pfizer |
Country | United Kingdom |
Sector | Private |
PI Contribution | The University of Dundee licenced the background IP around the projects chemical matter and biological model systems. The University of Dundee team are developing assays and support for high-throughput screening. The majority of the projects biology work is conducted by the Dundee team. The Dundee team are also providing Medicinal Chemistry and Project management expertise for the project. |
Collaborator Contribution | In addition to fully funding University of Dundee activities, Pfizer are providing access to compound libraries, models and drug discovery expertise. The project is part of the Pfizer-RDRU, with Pfizer staff members providing Project management and technical expertise to the project. |
Impact | Projects status is confidential |
Start Year | 2015 |
Description | Fragment screening |
Organisation | Duke University |
Country | United States |
Sector | Academic/University |
PI Contribution | Conducted screen. |
Collaborator Contribution | Provided target. |
Impact | Manuscript in preparation. |
Start Year | 2012 |
Description | Imaging of echogenic microbubbles and liposomes |
Organisation | European Commission |
Department | Seventh Framework Programme (FP7) |
Country | European Union (EU) |
Sector | Public |
PI Contribution | Development of equipment and imaging protocols |
Collaborator Contribution | Testing of equipment and development of software and hardware |
Impact | Results leading to possible future collaboration. Multidisciplinary-physics, chemistry, biology. |
Start Year | 2011 |
Description | Open innovation (AZ-OGA) |
Organisation | AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | The University of Dundee will use their OGA assay platform to screen the AZ compound libraries in order to identify new classes of OGA inhibitor. If suitable compounds are identified The University of Dundee will conduct structural biology, Medicinal chemistry and associated drug discovery activities to develop the hit compounds toward in vivo leads. |
Collaborator Contribution | AZ will provide access to AZ screening facilities and will provide access to proprietary compound libraries. |
Impact | Project in early stages and no outputs generated to date. |
Start Year | 2016 |
Title | IMPROVED SPERM FUNCTION/ACTIVITY |
Description | The present invention concerns phosphodiesterase inhibitors which may be used to modulate sperm motility, activity and/or function. Moreover the invention provides modulators of PDElGa which may be used to modulate the physiological processes occurring within a sperm cell. |
IP Reference | WO2013054111 |
Protection | Patent application published |
Year Protection Granted | 2013 |
Licensed | No |
Impact | Ongoing drug discovery programmes. |
Title | N-MYRISTOYL TRANSFERASE INHIBITORS |
Description | Compounds with potential for therapy in neglected diseases and cancer. The MRC funded devolved portfolio funded a project in the cancer therapeutic area. |
IP Reference | EP2323987 |
Protection | Patent application published |
Year Protection Granted | 2011 |
Licensed | No |
Impact | Collaboration with an international group. |
Title | Surgical tissue anchor |
Description | A means of displacing internal organs to prevent them from obstructing a minimal access surgical procedure. |
IP Reference | GB1100902.4 |
Protection | Patent application published |
Year Protection Granted | 2012 |
Licensed | Yes |
Impact | None other than licence |
Title | NMT inhibitors for cancer |
Description | NMT inhibitor developed at UoD Drug Discover Unit licenced to Pacylex. Molecule through and about to go into a number of phase 1 and phase 2 clinical studies for various cancers. Fast-tracked by FDA. |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Early clinical assessment |
Year Development Stage Completed | 2022 |
Development Status | Under active development/distribution |
Clinical Trial? | Yes |
Impact | Companion prognostic tool developed by Pacylex |
URL | http://www.pacylex.com |
Title | NMT inhibitors for cancer |
Description | The NMT inhibitors that were characterised for their effect in cancer under this award have been licenced to Pacylex. The background biology has now been established giving a rationale for treatment in specific cancers. The molecule is entering phase 1 clinical trials in Q1 2021 |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Initial development |
Year Development Stage Completed | 2021 |
Development Status | Under active development/distribution |
Impact | No other notable impacts at this stage. |
URL | https://www.pacylex.com/ |
Description | Conference proceedings (AM 2014) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Cox BF, Eisma R, Rube MA, Immel E, Gueorguieva M, McLeod H, Melzer A. Developing Thiel Soft-Fix Cadavers as a suitable model for iMRI training and research. Abstract, Presented at the 9th International Interventional MRI Symposium, September, 2012. Pendleton M, Cox BF, Saliev T, Rube MA, McLeod H, Melzer A. Imaging of Vessel Patency in Thiel Embalmed Liver. Oral Presentation, Presented at Fifth Image Guided Therapy Workshop of the National Center for Image-Guided Therapy, September, 2012. Cox BF, McLeod H, Rube MA, Vinnicombe S, Holbrook AB, Eisma R, Saliev T, Karakitsios I, Melzer A. MR real-time tracking of hepatic motion during respiration in a Thiel Soft-fix cadaver. Oral Presentation, Presented at the 46th Annual Conference of the Deutsche Gesellschaft für Biomedizinische Technik, September 2012. Rube MA, Immel E, Cox B, Melzer A. Towards Interventional MRI: Semi-Active Device Localization in Phantom Experiments and in a Thiel Embalmed Human Cadaver Model. Oral Presentation, Presented at the 26th International Congress and Exhibition of Computer Assisted Radiology and Surgery, June 2012. McLeod H, Cox B, Eisma R, Mathew S, Melzer A, Houston G. Thiel Embalmed Human Cadaver: Vascular Model Development for Teaching and Training. Poster session presented: College Research Symposium, University of Dundee, Crieff, Feb 20th - 21st 2014. McLeod H, Cox B, Eisma R, Immel E, Roberston J, Melzer A, Houston G. Thiel Embalmed Human Cadaver: Venous Modeling. Poster Session presented at 26th Society for Medical Innovaton and Technology, Shanghai, 18- 21st Sept 2014. McLeod H, Cox B, Eisma R, Immel E, Pendleton M, Melzer A, Houston G. Thiel Embalmed Human Cadaver: Extracorporeal Central Arterial Circulatory Model Development. Oral Presentation presented at 26th Society for Medical Innovaton and Technology, Shanghai, 18- 21st Sept 2014. Continuation of the demonstration of the strengths of this relatively new technology area amongst the academic community and those responsible for future clinical training and practice. |
Year(s) Of Engagement Activity | 2012,2014 |
Description | Conference proceedings (AM group) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Paper Presentation |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Gueorguieva M., Yeo D., Eisma R. and Melzer A., (2012). MR Imaging of Thiel embalmed human cadavers. 20th Annual meeting of the International Society for Magnetic Resonance in Medicine, ISMRM, Melbourne, Australia • Rube M., Kokkalis E., Immel E., Gueorguieva M., Eisma R. And Melzer A., (2012). Training and Testing Environment for MR-guided Vascular Interventions. 20th Annual meeting of the International Society for Magnetic Resonance in Medicine, ISMRM, Melbourne, Australia • Eisma R., Gueorguieva M., Immel E., Toomey R., Soames R., and Melzer A., (2012). Thiel embalmed cadavers as a model for research and training in minimally invasive therapies - a study of respiratory liver displacement. Joint Winter Meeting of Anatomical Societies, Dec. 2011 , Cardiff, UK. To be published in Journal of Anatomy. • Toomey R.J., Gueorguieva M, Immel E, Houston J.G., McLeod G.A., Eisma R., Melzer A. (2011). Value and Techniques of Multi-Modality Imaging of Thiel Soft-Embalmed Cadavers for Research, Training and Device Development (Educational Exhibit). 97th Annual Meeting of the Radiological Society of North America, RSNA, Chicago, Illinois, USA • Gueorguieva M. J., Immel E, Eisma R, and Melzer A., (2010). Improvement of MR Imaging of Thiel Embalmed Human Cadavers (Abstract). Minimally Invasive Therapy & Allied Technologies, MITAT, Vol. 19, Supplement 1: 40-41 • Immel E., Eisma R., Gueorguieva M., Fernandez-Gutierrez F., Houston G., and Melzer A., (2010). Comparison of X-Ray and MRI guided Implantation of a Resonant Balloon Expandable Stent in a Thiel Embalmed Cadaver (Abstract). Minimally Invasive Therapy & Allied Technologies, MITAT, Vol. 19, Supplement 1: 22-23 • Immel E., Eisma R., Gueorguieva M., Fernandez F., Houston G., and Melzer A., (2010). MRI guided Implantation of a Resonant Vena Cava Filter in a Thiel Embalmed Cadaver (Abstract). Minimally Invasive Therapy & Allied Technologies, MITAT, Vol. 19, Supplement 1: 50-51 " Thiel soft-fix embalming: the new face of anatomy in Dundee" Roos Eisma, presented at the Institute for Anatomical Sciences Autumn Scientific Meeting, St Andrews, 31 August 2012 and at the Association of Anatomical Pathology Technicians Conference, Bristol, 22 September 2012 Demonstrate utility of this relatively new technology area amongst the academic community.This will lead to increased collaborative opportunities and uptake of the technology that will impact on future clinical training and practice. |
Year(s) Of Engagement Activity | 2010,2011,2012 |
Description | Conference proceedings (AM/2013) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | Invited session and Chair at CARS 2013 Organised the 2nd Eurpoean FUS Therapy Symposium Rome 10-11th October 2013 Demonstration that this relatively newtechnology has lead to increased collbaorative opportunities and uptake of the technology that will impact on future clinical training and practice. |
Year(s) Of Engagement Activity | 2013 |
Description | Lecture to GP's |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | Yes |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Talk sparked questions and discussion. It is anticipated that there will be better informed treatment decisions as a result of the talk . The talk was only delivered on 28th October 2014 and as such feedback is expected over the next few months. |
Year(s) Of Engagement Activity | 2014 |
Description | Open Doors Day |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | General public attended . Raise awareness of science being done at College of Life Sciences, University of Dundee via exhibits and workshops. |
Year(s) Of Engagement Activity | 2011,2012 |